niacinamide has been researched along with Carcinoma, Basal Cell in 23 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are common cancers that are caused principally by ultraviolet (UV) radiation." | 2.80 | A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. ( Chen, AC; Chinniah, N; Choy, B; Dalziell, RA; Damian, DL; Dhillon, HM; Fernández-Peñas, P; Halliday, GM; Kricker, A; Martin, AJ; McKenzie, CA; Scolyer, RA; St George, G; Vardy, JL, 2015) |
| "The incidence of non-melanoma skin cancer (NMSC) is dramatically increasing worldwide, despite the increased use of improved sunscreens." | 2.61 | Skin cancer prevention: a review of current topical options complementary to sunscreens. ( Chipps, L; Herrmann, J; Rosenthal, A; Stoddard, M, 2019) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "We observed more cases of skin cancer during sorafenib treatment than during sunitinib treatment for advanced RCC; median MKI treatment duration before the identification of skin cancer was longer than 1 year." | 2.49 | Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. ( Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (73.91) | 24.3611 |
| 2020's | 6 (26.09) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, NC | 2 |
| Martin, AJ | 6 |
| Snaidr, VA | 1 |
| Eggins, R | 1 |
| Chong, AH | 1 |
| Fernandéz-Peñas, P | 3 |
| Gin, D | 1 |
| Sidhu, S | 1 |
| Paddon, VL | 1 |
| Banney, LA | 1 |
| Lim, A | 1 |
| Upjohn, E | 1 |
| Schaider, H | 1 |
| Ganhewa, AD | 1 |
| Nguyen, J | 1 |
| McKenzie, CA | 3 |
| Prakash, S | 1 |
| McLean, C | 1 |
| Lochhead, A | 1 |
| Ibbetson, J | 1 |
| Dettrick, A | 1 |
| Landgren, A | 1 |
| Allnutt, KJ | 1 |
| Allison, C | 1 |
| Davenport, RB | 1 |
| Mumford, BP | 1 |
| Wong, B | 1 |
| Stagg, B | 1 |
| Tedman, A | 1 |
| Gribbin, H | 1 |
| Edwards, HA | 1 |
| De Rosa, N | 1 |
| Stewart, T | 1 |
| Doolan, BJ | 1 |
| Kok, Y | 1 |
| Simpson, K | 1 |
| Low, ZM | 1 |
| Kovitwanichkanont, T | 1 |
| Scolyer, RA | 3 |
| Dhillon, HM | 2 |
| Vardy, JL | 2 |
| Chadban, SJ | 1 |
| Bowen, DG | 1 |
| Chen, AC | 4 |
| Damian, DL | 8 |
| Schmults, CD | 1 |
| Jambusaria-Pahlajani, A | 1 |
| Ruiz, E | 1 |
| Trepanowski, N | 1 |
| Kim, DY | 1 |
| Hartman, RI | 1 |
| Tee, LY | 1 |
| Sultana, R | 1 |
| Tam, SYC | 1 |
| Oh, CC | 1 |
| Arzeno, J | 1 |
| Leavitt, E | 1 |
| Lonowski, S | 1 |
| Kim, J | 1 |
| Minocha, R | 2 |
| Halliday, GM | 4 |
| Nestor, L | 1 |
| Clowry, J | 1 |
| Molloy, K | 1 |
| Connolly, M | 1 |
| Salim, A | 1 |
| Tobin, AM | 1 |
| Gilmore, SJ | 1 |
| Lyons, JG | 1 |
| Madore, J | 1 |
| Rosenthal, A | 1 |
| Stoddard, M | 1 |
| Chipps, L | 1 |
| Herrmann, J | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Breaker, K | 1 |
| Naam, M | 1 |
| La Rosa, FG | 1 |
| Flaig, IP | 1 |
| Flaig, TW | 1 |
| Choy, B | 1 |
| Dalziell, RA | 1 |
| Kricker, A | 1 |
| St George, G | 1 |
| Chinniah, N | 1 |
| Sidaway, P | 1 |
| Hajdenberg, J | 1 |
| Zhao, Y | 1 |
| Drago, F | 1 |
| Ciccarese, G | 1 |
| Parodi, A | 1 |
| Escudero-Góngora, MM | 1 |
| Degen, A | 1 |
| Satzger, I | 1 |
| Voelker, B | 1 |
| Kapp, A | 1 |
| Hauschild, A | 1 |
| Gutzmer, R | 1 |
| Surjana, D | 1 |
| Moloney, FJ | 1 |
8 reviews available for niacinamide and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Niacinamide; | 2021 |
Nicotinamide for skin cancer chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immune Tolerance; Keratosis, Ac | 2017 |
Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Repair; Humans; Immunomodulation; Mela | 2018 |
Skin cancer prevention: a review of current topical options complementary to sunscreens.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibit | 2019 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell | 2013 |
Nicotinamide: New Indications in Dermatology.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; Clinical Trials, Phase III as Topi | 2016 |
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female | 2010 |
5 trials available for niacinamide and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Topics: Antineoplastic Agents; Australia; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; | 2023 |
Nicotinamide for prevention of nonmelanoma skin cancers: a change in practice?
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cost of Illness; Humans; Keratosis, Actinic; Niacin | 2017 |
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.
Topics: Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Count; Humans; Incidence; Macr | 2019 |
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Method | 2015 |
Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neopl | 2012 |
10 other studies available for niacinamide and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. Reply.
Topics: Carcinoma, Basal Cell; Chemoprevention; Humans; Niacinamide; Skin Neoplasms; Transplant Recipients | 2023 |
Current Practices for Preventative Interventions for Nonmelanoma Skin Cancers Among Dermatologic Surgeons.
Topics: Acitretin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatologic Agents; Humans; Institution | 2021 |
Nicotinamide and skin cancer chemoprevention: The jury is still out.
Topics: Bayes Theorem; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; | 2018 |
Skin cancer: Nicotinamide reduces new skin cancer risk.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
ACP Journal Club. In high-risk patients, oral nicotinamide reduced number of new nonmelanoma skin cancers during treatment.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |
Nicotinamide for Skin-Cancer Chemoprevention.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Keratosis, Actinic; Male; Niacinami | 2016 |